Business Description
Bioventix PLC
ISIN : GB00B4QVDF07
Total Employee Number:
16Description
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.85 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 43.9 | |||||
Beneish M-Score | -2.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.6 | |||||
3-Year EBITDA Growth Rate | 2.4 | |||||
3-Year EPS without NRI Growth Rate | -0.6 | |||||
3-Year FCF Growth Rate | -2.6 | |||||
3-Year Book Growth Rate | -0.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.12 | |||||
Quick Ratio | 5.76 | |||||
Cash Ratio | 2.66 | |||||
Days Inventory | 252.05 | |||||
Days Sales Outstanding | 132.36 | |||||
Days Payable | 487.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 11.3 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 9.38 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.43 | |||||
Operating Margin % | 77.92 | |||||
Net Margin % | 59.29 | |||||
EBITDA Margin % | 78.44 | |||||
FCF Margin % | 61.89 | |||||
OCF Margin % | 62.15 | |||||
ROE % | 65.87 | |||||
ROA % | 57.34 | |||||
ROIC % | 117.71 | |||||
3-Year ROIIC % | -3.4 | |||||
ROC (Joel Greenblatt) % | 247.32 | |||||
ROCE % | 86.56 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.38 | |||||
Forward PE Ratio | 25.1 | |||||
PE Ratio without NRI | 11.38 | |||||
Shiller PE Ratio | 10.82 | |||||
Price-to-Owner-Earnings | 8.53 | |||||
PEG Ratio | 2.03 | |||||
PS Ratio | 6.75 | |||||
PB Ratio | 7.67 | |||||
Price-to-Tangible-Book | 7.66 | |||||
Price-to-Free-Cash-Flow | 10.91 | |||||
Price-to-Operating-Cash-Flow | 10.85 | |||||
EV-to-EBIT | 8.01 | |||||
EV-to-EBITDA | 7.96 | |||||
EV-to-Revenue | 6.24 | |||||
EV-to-FCF | 10.08 | |||||
Price-to-GF-Value | 0.45 | |||||
Price-to-Projected-FCF | 0.96 | |||||
Price-to-DCF (Earnings Based) | 0.47 | |||||
Price-to-DCF (FCF Based) | 0.41 | |||||
Price-to-Median-PS-Value | 0.37 | |||||
Price-to-Peter-Lynch-Fair-Value | 2 | |||||
Price-to-Graham-Number | 1.97 | |||||
| Price-to-Net-Current-Asset-Value | 8.31 | |||||
| Price-to-Net-Cash | 25.36 | |||||
Earnings Yield (Greenblatt) % | 12.48 | |||||
FCF Yield % | 9.29 | |||||
Forward Rate of Return (Yacktman) % | 14.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BVNXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioventix PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 16.907 | ||
| EPS (TTM) ($) | 1.894 | ||
| Beta | 0.1201 | ||
| 3-Year Sharpe Ratio | -6.96 | ||
| 3-Year Sortino Ratio | -3.11 | ||
| Volatility % | 6.37 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 14.71147 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 14.71147 - 14.71147 | ||
| Shares Outstanding (Mil) | 5.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioventix PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioventix PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-04 14:00 | In 149 days | ||
| Annual report for 2026 | 2026-11-11 | In 125 days | ||
| Fourth quarter earnings results for 2026 | 2026-10-27 | In 110 days | ||
| GBP 0.700000 Cash Dividend | 2026-04-09 | 14.71 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-03-30 | 14.71 (+0.00%) | ||
| General meeting for 2025 | 2025-12-04 14:00 | -- | ||
| Annual report for 2025 | 2025-11-11 | -- | ||
| Fourth quarter earnings results for 2025 | 2025-10-27 | -- | ||
| Second quarter earnings results for 2025 | 2025-03-31 | -- | ||
| General meeting for 2024 | 2024-12-05 14:00 | -- |
Show
Entries
Bioventix PLC Frequently Asked Questions
What is Bioventix PLC(BVNXF)'s stock price today?
The current price of BVNXF is $14.71. The 52 week high of BVNXF is $14.71 and 52 week low is $14.71.
When is next earnings date of Bioventix PLC(BVNXF)?
The next earnings date of Bioventix PLC(BVNXF) is 2026-10-27 Est..
Does Bioventix PLC(BVNXF) pay dividends? If so, how much?
Bioventix PLC(BVNXF) does not pay dividend.
Guru Commentaries on OTCPK:BVNXF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Bioventix PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers